A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2018
At a glance
- Drugs Poziotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms POZITIVE20-1
- Sponsors Spectrum Pharmaceuticals
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 23 Apr 2018 According to a Spectrum Pharmaceuticals media release, the company is planning study centre expansion in the U.S. and other countries.
- 10 Apr 2018 According to a Spectrum Pharmaceuticals media release, as enrollment in MD Andersons phase 2 study (NCT03066206) nears completion, patient enrolling will begin soon in this ongoing Spectrums Phase 2 study.